Reference is made to the stock exchange announcement published by Observe
Medical ASA (the "Company") on 22 November 2023, regarding the extraordinary
general meeting's approval of the contemplated rights issue raising gross
proceeds of up to NOK 55 million (the "Rights Issue"). Reference is further made
to the stock exchange announcement published on 24 November 2023 regarding the
approval by the Financial Supervisory Authority of Norway (Nw. Finanstilsynet)
of the prospectus prepared by the Company for the offer and listing on the Oslo
Stock Exchange (Euronext Expand) of up to 211,538,461 Offer Shares in the Rights
Issue.

The subscription period in the Rights Issue will commence on 28 November 2023 at
09:00 hours (CET). As part of this process, subscription rights in the Rights
Issue have been allocated to primary insiders and their close associates.

Please see the attached mandatory notifications of trade for information
regarding the primary insiders' and their close associates' receipt of
subscription rights in the Rights Issue.

This information is subject to the disclosure requirements pursuant to article
19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian
Securities Trading Act.